Tropifexor (LJN452) in NASH

FLIGHT-FXR Study: Tropifexor (LJN452) in NASH: phase 2b (interim results)
Sanyal AJ, AASLD 2018, Abs. LB-23

DOWNLOAD THIS SLIDE KIT

BROWSE SLIDES

Design

Endpoints

  • Safety, liver fat content (MRI-PDFF), liver biochemistry

Results (parts A and B)

Geometric mean % change from baseline in ALT (IU/L), 95% CI – Parts A and B

Geometric mean % change from baseline in GGT (IU/L), 95% CI – Parts A and B

Safety

  • Comparable rates of adverse events, including pruritus, for Tropifexor and placebo
  • Mild dose response increase of LDL and decrease of HDL, unchanged triglycerides